Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial - The Lancet Haematology
Heavy water labeling in CLL patients before ibrutinib therapy: workflow... | Download Scientific Diagram
IMBRUVICA® (ibrutinib) - Cancer Therapy Advisor
Cheadaigh FDA na SA Johnson & Johnson / Imbruvica (Ibrutini) le haghaidh 11 thásc agus 6 le haghaidh cóireála leoicéime! - Nuacht tionscail - Nuacht - Hefei Home Sunshine Pharmaceutical Technology Co., Ltd
Janssen's Imbruvica secures label expansion in Europe in chronic lymphocytic leukaemia | Pharmafile
These highlights do not include all the information needed to use IMBRUVICA safely and effectively. See full prescribing information for IMBRUVICA. IMBRUVICA ® (ibrutinib) capsules, for oral use IMBRUVICA ® (ibrutinib) tablets,
BeiGene nabs landmark FDA nod for Brukinsa, kicking off challenge against blockbuster Imbruvica | FiercePharma
Imbruvica (Ibrutinib) for the Treatment of Mantle Cell Lymphoma (MCL) - Clinical Trials Arena
Fourth breakthrough designation for Janssen's Imbruvica - PharmaTimes
Patient Resources & Information for IMBRUVICA® (ibrutinib)
Imbruvica 560 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC) - (emc)
FDA expands Imbruvica's label to include survival data - PharmaTimes
Prototype Label demonstrating the Pair Plot module and highlighting... | Download Scientific Diagram
These highlights do not include all the information needed to use IMBRUVICA safely and effectively. See full prescribing information for IMBRUVICA. IMBRUVICA ® (ibrutinib) capsules, for oral use IMBRUVICA ® (ibrutinib) tablets,
What is imbruvica?
RESONATE - Study Design | IMBRUVICA®
Ibrutinib - Wikipedia
BeiGene's Phase III Waldenström's study misses mark, but with a possible silver lining - MedCity News
J&J pushes to expand Imbruvica label after clinical success - PMLiVE
The Lancet Oncology on Twitter: "Presenting now at #ASH18: Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in firstline treatment of chronic lymphocytic #leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial ...
Supplemental Materials for Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study - The Lancet Oncology
Janssen and AbbVie's Imbruvica: fresh EC approvals
AbbVie eyes Imbruvica expansion in CLL as Gazyva pairing hits its marks | FiercePharma
